Supplementary Table 1 Life expectancy eliminating death from gastric cancer in late elderly patients

Life expectancy eliminating death from gastric cancer (years)

General population based on the NSO data Postoperative patients in our studya
Age 2005 2009 Age 2005 – 2009
80 years 8.4 9.3 80 – 84 years 8.1
85 years 6.0 6.7 ≥ 85 years 4.3
NSO, National Statistical Office.
a
Calculated from the survival curves in FIG. 2.
Supplementary Table 2 The chemotherapeutic regimens in patients who received adjuvant chemotherapy (n =
111)

Patients aged Patients aged

60 – 64 years 75 – 79 years
(n = 97) (n = 14)
5-FU (5-fluorouracil) 12 (12.4 %) 0 (0.0 %)
FP (5-FU + cisplatin) 26 (26.8 %) 1 (7.1 %)
FM (5-FU + mitomycin) 8 (8.2 %) 0 (0.0 %)
FL (5-FU + leucovorin) 3 (3.1 %) 1 (7.1 %)
UFT-E (tegafura and uracil) 1 (1.0 %) 3 (21.4 %)
TS-1 (tegafura, gimeracil and oteracil potassium) 18 (18.6 %) 3 (21.4%)
TS-1 + cisplatin 1 (1.0 %) 0 (0.0 %)
XP (capecitabine + cisplatin) 11 (11.3 %) 0 (0.0 %)
XELOX (capecitabine + oxaliplatin) 7 (7.2 %) 2 (14.3 %)
FOLFOX (leucovorin + fluorouracil + oxaliplatin) 2 (2.1 %) 1 (7.1 %)
Taxol + cisplatin 1 (1.0 %) 0 (0.0 %)
Paclitaxel + carboplatin 0 (0.0 %) 1 (7.1 %)
Etoposide + cisplatin 1 (1.0 %) 0 (0.0 %)
Unknown 6 (6.2 %) 2 (14.3 %)
a
a prodrug of fluorouracil
Supplementary Table 3 Recurrence patterns according to age in recurred gastric cancer patients (n = 108)
Patients aged Patients aged Patients aged
60 – 64 years 75 – 79 years ≥ 80 years
(n = 64) (n = 29) (n = 15)
Locoregionala 24 (37.5 %) 6 (20.7 %) 4 (26.7 %)
Hematogenousb 9 (14.1 %) 3 (10.3 %) 4 (26.7 %)
Peritonealc 22 (34.4 %) 15 (51.7 %) 3 (20.0 %)
Extraabdominal lymph nodes 2 (3.1 %) 0 (0.0 %) 0 (0.0 %)
Unknown 5 (7.8 %) 2 (6.9 %) 3 (20.0 %)
Mixed
Locoregional + Hematogenous 1 (1.6 %) 1 (3.4 %) 0 (0.0 %)
Locoregional + Peritoneal 1 (1.6 %) 2 (6.9 %) 0 (0.0 %)
Locoregional + Hematogenous + Peritoneal 0 (0.0 %) 0 (0.0 %) 1 (6.7 %)
a
Locoregional recurrence included tumor in adjacent organs, including in the gastric bed, anastomosis, gastric stump, or regional lymph
nodes (perigastric, left gastric, common hepatic, celiac, hepatoduodenal, retropancreatic, mesenteric, and paraaortic).30
b
Hematogenous recurrence included recurrence in liver, lung, bone, brain, or other distant sites. 30
c
Peritoneal recurrence was peritoneal seeding or Krukenberg’s tumor. 30